Rocket One Subsidiary Hoth Ends HT-001 Phase 2a Trial Early After Positive Interim Results

Bitget2026/11/03 13:17

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Rocket One subsidiary Hoth Therapeutics will end its Phase 2a HT-001 trial early following strong interim efficacy results.
Hoth plans to seek FDA feedback on a potential Phase 3 program; initiation depends on regulatory feedback and required development work.
HT-001 targets skin toxicities associated with EGFR inhibitor cancer therapies. The treatment remains investigational.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rocket One Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611030817PR_NEWS_USPR_____NY87411) on November 03, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Rocket One Subsidiary Hoth Ends HT-001 Phase 2a Trial Early After Positive Interim Results

You may also like

Crypto prices